secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001193125-23-001591
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alpha Healthcare Acquisition Corp. III merges with Carmell Therapeutics at $150M implied equity value
--------------------------------------------------------------------------------

- Carmell shareholders receive 15M ALPA Class A shares; implied Carmell equity value $150M.
- Combined company expected market cap ~$328M; Carmell shareholders own ~46% post-close.
- Transaction expected to close H1 2023; combined co. to list on Nasdaq as 'CTCX'.
- Carmell is a Phase 2 biotech with allogeneic plasma-based biomaterials; FDA Fast Track for tibia fracture.
- Rajiv Shukla to become Chairman, Randy Hubbell to serve as CEO of combined company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000119312523001591/0001193125-23-001591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000119312523001591/d411625d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-001591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer